ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM),…
ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals
Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE…
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
Garching / Munich, Germany, and Grenoble, France, June 16, 2025 – ITM Isotope…
RadioMedix Debuts Proprietary bench top Pb Generator to Support Targeted Alpha Therapy Development
New bench top ²¹²Pb generator to expand clinical-grade isotope supply for targeted…
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
PETACH TIKVA, Israel, June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ:…
